Activation of pyruvate kinase-R with etavopivat (FT-4202) is well tolerated, improves anemia, and decreases intravascular hemolysis in patients with sickle cell disease treated for up to 12 weeks

Authors
Category Primary study
JournalHemaSphere
Year 2022
This article has no abstract
Epistemonikos ID: ccf1d4d77879ec1d94060aac15bcc1dfcc91e944
First added on: Feb 13, 2025